货号 (SKU)

包装规格

是否现货

价格

数量

Ab176615-100μg

100μg

现货

Ab176615-1mg

1mg

现货

Ab176615-5mg

5mg

现货

Ab176615-10mg

10mg

期货

基本信息

产品名称	Ravulizumab (anti-Complement C5), 补体 C5 抑制剂
别名	雷夫利珠单抗 \| 雷维珠单抗(抗补体 C5)
英文别名	Anaphylatoxin C5a analog antibody \| C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4 antibody \| C5 antibody \| C5a anaphylatoxin antibody \| C5a antibody \| C5b antibody \| CO5_HUMAN antibody \| Complement C5 alpha'' chain antibody \| Complemen
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	C5
种属反应性	人(Human),小鼠(Mouse),恒河猴(Rhesus monkey),食蟹猴(Cynomolgus monkey)
偶联	Unconjugated
作用类型	抑制剂
作用机制	补体 C5 抑制剂

产品属性

克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG2
轻链亚型	kappa
SDS-PAGE	145.80 kDa
纯化方法	Protein A purified
纯度	>95%
物理外观	Liquid
储存缓冲液	Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	1803171-55-2
分子类型	抗体

图片

SEC: Ravulizumab (anti-Complement C5) (Ab176615)

Ravulizumab (anti-Complement C5) (Ab176615) - SEC
The purity of Ravulizumab (anti-Complement C5) (Ab176615) is more than 95% verified by HPLC.

关联靶点（人）

C5 Tclin 补体 C5(Complement C5) (0 活性数据)

点击查看靶蛋白信息： C5

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

安全和危险性（GHS）

SDS英文版

质量标准

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到7个结果

批号(Lot Number)	证书类型	日期	货号
ZJ24F1214702	分析证书	24-12-03	Ab176615
ZJ24F1214701	分析证书	24-12-03	Ab176615
ZJ24F0809460	分析证书	24-08-12	Ab176615
ZJ24F0809459	分析证书	24-08-12	Ab176615
ZJ24F0809458	分析证书	24-08-12	Ab176615
ZJ23F1202178	分析证书	23-12-22	Ab176615
ZJ23F1202177	分析证书	23-12-22	Ab176615

可替换产品

参考文献

1. Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, Noji H, Kitamura K, Eto T, Takahashi T et al.. (2014) Genetic variants in C5 and poor response to eculizumab.. N Engl J Med, 370 (7): (632-9). [PMID:24521109]
2. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.. Nat Biotechnol, 25 (11): (1256-64). [PMID:17989688]
3. Fernandez, H N HN and Hugli, T E TE.. (1978) Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a.. The Journal of biological chemistry, (10): [PMID:690134]
4. Haviland, D L DL, Haviland, J C JC, Fleischer, D T DT, Hunt, A A and Wetsel, R A RA.. (1991) Complete cDNA sequence of human complement pro-C5. Evidence of truncated transcripts derived from a single copy gene.. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:1984448]
5. Bohnsack, J F JF, Mollison, K W KW, Buko, A M AM, Ashworth, J C JC and Hill, H R HR.. (1991) Group B streptococci inactivate complement component C5a by enzymic cleavage at the C-terminus.. The Biochemical journal, (1): [PMID:1996961]
6. Lundwall, A B AB and 7 more authors.. (1985) Isolation and sequence analysis of a cDNA clone encoding the fifth complement component.. The Journal of biological chemistry, (25): [PMID:2579066]
7. Zuiderweg, E R ER and Fesik, S W SW.. (1989) Heteronuclear three-dimensional NMR spectroscopy of the inflammatory protein C5a.. Biochemistry, (21): [PMID:2730871]
8. Zuiderweg, E R ER, Nettesheim, D G DG, Mollison, K W KW and Carter, G W GW.. (1989) Tertiary structure of human complement component C5a in solution from nuclear magnetic resonance data.. Biochemistry, (10): [PMID:2784981]
9. Wetsel, R A RA and 5 more authors.. (1988) Molecular analysis of human complement component C5: localization of the structural gene to chromosome 9.. Biochemistry, (8): [PMID:3365401]
10. Zuiderweg, E R ER, Mollison, K W KW, Henkin, J J and Carter, G W GW.. (1988) Sequence-specific assignments in the 1H NMR spectrum of the human inflammatory protein C5a.. Biochemistry, (17): [PMID:3408713]
11. Wang, X X and 7 more authors.. (1995) Inherited human complement C5 deficiency. Nonsense mutations in exons 1 (Gln1 to Stop) and 36 (Arg1458 to Stop) and compound heterozygosity in three African-American families.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:7730648]
12. Zhang, X X, Boyar, W W, Galakatos, N N and Gonnella, N C NC.. (1997) Solution structure of a unique C5a semi-synthetic antagonist: implications in receptor binding.. Protein science : a publication of the Protein Society, [PMID:9007977]
13. Zhang, X X, Boyar, W W, Toth, M J MJ, Wennogle, L L and Gonnella, N C NC.. (1997) Structural definition of the C5a C terminus by two-dimensional nuclear magnetic resonance spectroscopy.. Proteins, [PMID:9188742]
14. Chen, Z Z and 5 more authors.. (1998) Residues 21-30 within the extracellular N-terminal region of the C5a receptor represent a binding domain for the C5a anaphylatoxin.. The Journal of biological chemistry, (24): [PMID:9553099]
15. Delgado-Cerviño, Eva E, Fontán, Gumersindo G and López-Trascasa, Margarita M.. (2005) C5 complement deficiency in a Spanish family. Molecular characterization of the double mutation responsible for the defect.. Molecular immunology, [PMID:15488949]
16. Bramham, Janice J and 5 more authors.. (2005) Functional insights from the structure of the multifunctional C345C domain of C5 of complement.. The Journal of biological chemistry, (18): [PMID:15598652]
17. Pfarr, Nicole N and 12 more authors.. (2005) Linking C5 deficiency to an exonic splicing enhancer mutation.. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:15778377]
18. Hillebrandt, Sonja S and 13 more authors.. (2005) Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans.. Nature genetics, [PMID:15995705]
19. Singer, Andrew L AL and 9 more authors.. (2009) Successful liver transplantation for Budd-Chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria treated with the anti-complement antibody eculizumab.. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, [PMID:19399743]
20. Kelly, Richard; Richards, Stephen; Hillmen, Peter and Hill, Anita.. (2009) The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab.. Therapeutics and clinical risk management, [PMID:20011245]
21. Laursen, Nick S NS and 5 more authors.. (2011) Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex.. The EMBO journal, (2): [PMID:21217642]
22. Jore, Matthijs M and 7 more authors.. (2016) Structural basis for therapeutic inhibition of complement C5.. Nature structural & molecular biology, [PMID:27018802]
23. Reichhardt, Martin P and 8 more authors.. (2020) An inhibitor of complement C5 provides structural insights into activation.. Proceedings of the National Academy of Sciences of the United States of America, (7): [PMID:31871188]
24. Chen, X X, Ji, Z L ZL and Chen, Y Z YZ.. (2002) TTD: Therapeutic Target Database.. Nucleic acids research, (1): [PMID:11752352]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Ravulizumab (anti-Complement C5), 补体 C5 抑制剂

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

图片

关联靶点（人）

作用机制

安全和危险性（GHS）

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

可替换产品

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器

Ravulizumab (anti-Complement C5), 补体 C5 抑制剂

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

图片

关联靶点（人）

作用机制

安全和危险性（GHS）

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

可替换产品

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器